Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buspirone versus lorazepam adjunctive to risperidone for anxiety symptoms in adults with schizophrenia
IRCT20260428069196N1Phase 3Completed
- Sponsor
- University of Social Welfare and Rehabilitation Sciences
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in schizophrenia comparing Risperidone + buspirone, Risperidone + lorazepam and Risperidone + placebo (3 arms). Primary endpoint: Hamilton Anxiety Rating Scale score at week 8. Started Jul 2026; status: completed.
02
Drugs
buspironelorazepamrisperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on IRCT20260428069196N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260428069196N1.